Clinical evaluation of γ‐seminoprotein in prostate cancer

Kuriyama, Manabu; Takeuchi, Toshimi; I, Shinoda; Okano, Manabu; Nishiura, Tsuneo

doi:10.1002/pros.2990080310

Cited by 19 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The apparent molecular mass of γ-seminoprotein is 23 kDa (Hara et al 1971). Clinical studies (Kuriyama et al 1986;Siddall et al 1986) where PSA and γ-seminoprotein have been monitored in normal individuals and those with prostate cancer suggest a correlation between these marker proteins (Petraki et al 2006). Indeed, γ-seminoprotein appears to be identical to PSA (Lundwall and Lilja 1987;Schaller et al 1987;Wang et al 1982).…”

Section: Resultsmentioning

confidence: 89%

Human seminal proteinase and prostate-specific antigen are the same protein

et al. 2008

View full text Add to dashboard Cite

Human seminal proteinase and prostate-specific antigen (PSA) were each isolated from human seminal fluid and compared. Both are glycoproteins of 32-34 kDa with protease activities. Based on some physicochemical,enzymatic and immunological properties,it is concluded that these proteins are in fact identical. The protein exhibits properties similar to kallikrein-like serine protease, trypsin,chymotrypsin and thiol acid protease. Tests of the activity of the enzyme against some potential natural and synthetic substrates showed that bovine serum albumin was more readily hydrolysed than casein. The results of this study should be useful in purifying and assaying this protein. Based on published studies and the present results,the broad proteolytic specificity of human seminal proteinase suggests a role for this protein in several physiological functions.

show abstract

Section: Resultsmentioning

confidence: 89%

Human seminal proteinase and prostate-specific antigen are the same protein

et al. 2008

View full text Add to dashboard Cite

show abstract

“…), Roche (Basle, Switzerland) and Can-Ag (Urulu, Finland). Moreover, y-seminoprotein (y-Sm) (Chugai, Tokyo, Japan) in serum was also measured (9,10). For the assay of PSA-ACT, kits from Dainippon (Osaka, Japan) (11), Chugai (12), ElKEN (8) and Bayer (New York, NY) (13,14) were used.…”

Section: Methodsmentioning

confidence: 99%

Comparative Study of Assays for Prostate-specific Antigen Molecular Forms

Kuriyama

Uno

Ueno

et al. 1999

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

“…10,11 The ratio of g-Sm to PSA (g-Sm ratio) is recognized as a useful discriminator between prostate cancer and benign prostatic diseases. 12 Recently, g-Sm was demonstrated to correlate with free PSA; hence, g-Sm ratio theoretically had the same usefulness for detecting cancer as the free-to-total PSA ratio did.…”

Section: Introductionmentioning

confidence: 99%

Ratio of gamma‐seminoprotein to prostate‐specific antigen for the detection of prostate cancer: Its discrimination power could be influenced by the assay methods of PSA and/or gamma‐seminoprotein

et al. 1999

View full text Add to dashboard Cite

Background: The ratio of gamma-seminoprotein (g-Sm) and prostate-specific antigen (PSA) has been regarded as being superior over PSA alone as a discriminator between prostate cancer and benign prostatic diseases. In previous studies, PSA and g-Sm were measured by the Eiken kit and the old-version or revised Chugai kit, respectively. We compared the power of g-Sm ratio with that of PSA alone when using Markit-M PSA assay and the revised Chugai g-Sm assay. Methods: Fifty-three patients with prostate cancer having no metastasis and 116 with benign prostatic diseases were enrolled in this study. Prostate-specific antigen was measured by Markit-M kit and g-Sm was measured by the revised Chugai kit. The discrimination power of g-Sm ratio and PSA alone was evaluated with receiver operating characteristic (ROC) curves. Comparisons between prostate cancer and benign diseases were performed with Mann-Whitney U-test and Fisher's exact test. Results:The optimal cut-off value was set at 3.1 ng/mL for PSA and 0.935 for g-Sm ratio. Sensitivity, specificity and positive predictive value of PSA alone were 81.1, 81.0 and 66.2%, respectively, while those of g-Sm ratio were 73.6, 90.5 and 78.0%, respectively. There was no statistical significance in each value between PSA and g-Sm ratio. Areas under the ROC curves of PSA and g-Sm ratio were 0.881 and 0.866, respectively (P > 0.05). Conclusion: Contrary to the previous reports, g-Sm ratio and PSA were not different in the discrimination between prostate cancer and benign prostatic diseases, which suggested that the discrimination power of g-Sm ratio, and presumably that of the free PSA to total PSA ratio as well, could be considerably influenced by the assay kits for serum PSA and/or g-Sm (free PSA) used. Therefore, the clinical significance of g-Sm ratio should be evaluated for each PSA assay kit.

show abstract

Clinical evaluation of γ‐seminoprotein in prostate cancer

Cited by 19 publications

References 4 publications

Human seminal proteinase and prostate-specific antigen are the same protein

Human seminal proteinase and prostate-specific antigen are the same protein

Comparative Study of Assays for Prostate-specific Antigen Molecular Forms

Ratio of gamma‐seminoprotein to prostate‐specific antigen for the detection of prostate cancer: Its discrimination power could be influenced by the assay methods of PSA and/or gamma‐seminoprotein

Contact Info

Product

Resources

About